Ascletis Pharma has submitted two Investigational New Drug applications to the U.S. FDA for obesity treatments, disclosing that the second covers ASC36 35 FDC, a fixed-dose combination of the amylin agonist ASC36 and a peptide GLP-1R/GIPR dual agonist. Both applications are under review; acceptance…
Ascletis Pharma has submitted two Investigational New Drug applications to the U.S. Food and Drug Administration for potential obesity treatments. Both applications are now under review by the agency. If accepted, the filings would clear Ascletis to begin clinical trials in the United States.
The company disclosed the two submissions together but provided details on only one program. The second application covers ASC36 35 FDC, a fixed-dose combination product built from two active peptide-based components: ASC36, an amylin agonist, and a peptide GLP-1R/GIPR agonist. The dual agonist acts on two incretin receptors, the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor, both of which participate in glucose metabolism and appetite regulation.
The filing marks Ascletis's regulatory entry into the metabolic disease space. It also signals a broader pattern in obesity drug development. Rather than pursuing a single mechanism, sponsors are increasingly testing fixed combinations that join complementary metabolic regulators in one product. ASC36 35 FDC is designed to target multiple biological pathways underlying obesity, though the company has not released data showing how the two components behave together in humans.
The announcement contains a hard number and a conspicuous gap. The number is two: two IND applications submitted to the FDA for potential obesity treatments. The gap is that the company identified only the second application, the one covering ASC36 35 FDC. No details were provided about the active ingredient or program covered by the first IND application.
ASC36 35 FDC itself contains two active components. The first is ASC36, an amylin agonist. The second is a peptide GLP-1R/GIPR agonist, a single molecule that engages both incretin receptors. The term "fixed-dose combination" means the two actives are formulated into a single product rather than administered as separate injections. In metabolic disease this approach has precedent elsewhere in the industry, but for Ascletis it is a first step into obesity.
The company said the combination is designed to hit multiple biological pathways and mechanisms underlying obesity. What it did not say is just as important. Ascletis has not disclosed clinical trial design, patient populations, endpoints, or timelines for human studies. The two IND applications are under FDA review, but no dates for the submissions and no schedule for the agency's decision were included in the disclosure.
An IND application is the mechanism through which a sponsor requests permission from the FDA to ship an investigational drug across state lines for clinical study. Under the Federal Food, Drug, and Cosmetic Act, a drug that has not been approved cannot legally be transported for human testing without an active IND. Filing one is therefore the regulatory precondition for starting U.S. trials.
Once an IND is submitted, the FDA has a review period during which the agency can place the proposed study on clinical hold if it identifies safety concerns or deficiencies. If the agency raises no objections, the sponsor may proceed. Acceptance of an IND is not approval of the drug. It does not certify that the product works; it certifies that the proposed early-phase studies can go forward under specified conditions. The two Ascletis applications are now inside this review window. Whether the FDA accepts both, accepts one, or imposes a clinical hold depends entirely on the agency's review outcome.
Should the applications clear review, Ascletis remains bound by the full U.S. clinical research framework. Each trial site must have institutional review board approval, participants must give informed consent, and manufacturing of the peptide components must comply with current good manufacturing practice. The FDA also retains authority to pause or stop trials at any point if new safety information emerges. In short, IND acceptance is the start of a long regulatory path, not a milestone of efficacy.
ASC36 35 FDC pairs two hormone systems that regulate metabolism through different routes. Amylin, also known as islet amyloid polypeptide, is a 37-amino acid peptide co-secreted with insulin by pancreatic beta cells in response to meals. It slows gastric emptying, suppresses glucagon secretion, and promotes satiety through signaling in the area postrema and central nervous system. The only amylin-based drug in clinical use, pramlintide, has long established that this pathway can modify postprandial glucose and body weight in people with diabetes.
The peptide GLP-1R/GIPR agonist in the combination targets the two incretin receptors. GLP-1 receptor activation stimulates glucose-dependent insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite through central mechanisms. GIP receptor activation also potentiates insulin secretion and, in the setting of dual agonism, appears to complement GLP-1 effects. Dual GLP-1R/GIPR agonism has been clinically validated by tirzepatide, an approved drug for type 2 diabetes and obesity that has produced weight reduction substantially greater than that seen with GLP-1 receptor monotherapy.
The scientific rationale for combining an amylin agonist with a dual incretin agonist is that the pathways are complementary rather than redundant. Amylin signaling operates partly through the area postrema and central feeding circuits, while incretin signaling works through pancreatic islets, gut, and hypothalamic nuclei. By hitting distinct nodes in the appetite and glucose-regulating network, a fixed combination may achieve additive or synergistic weight loss, and may allow lower doses of each component to limit side effects such as nausea and gastrointestinal discomfort. That hypothesis is plausible but unproven. Whether two agonists formulated in one product produce effects that are additive, synergistic, or merely overlapping is an empirical question, and neither Ascletis nor anyone else has released human data on this specific pairing.
For researchers, the filing is a reminder that fixed-dose peptide combinations are becoming a standard test of the multi-pathway hypothesis in obesity. The appeal of a single product with two mechanisms is easy to state: one injection, potentially complementary pharmacology, and a simpler adherence story than two separate pens. But fixed-dose combinations constrain the dose ratio. Once the two actives are locked into one formulation, a trial cannot independently titrate one without the other, which complicates dose finding and makes the interpretation of adverse events more difficult.
For clinicians, the practical question is tolerability and efficacy at the combination dose. Both amylin agonism and dual incretin agonism carry gastrointestinal side-effect profiles, and nausea is the most common tolerability problem in this drug class. Whether co-formulation changes the tolerability of either component is unknown. If ASC36 35 FDC reaches the clinic, clinicians will want to see not just mean weight loss but discontinuation rates, the proportion of patients with nausea or vomiting, and whether the combination achieves weight loss at lower doses than either mechanism alone.
For the peptide supply chain, the program is a formulation and manufacturing challenge. The components are synthetic peptides, and the GLP-1R/GIPR agonist class has driven substantial investment in solid-phase peptide synthesis capacity in recent years. Amylin and its analogues, for their part, are known to be aggregation-prone, and human amylin has a well-documented capacity to form amyloid fibrils. Co-formulating an amylin agonist with a dual incretin peptide in a fixed-dose product requires compatible pH, ionic strength, and excipients, stability of both molecules over shelf life, and analytical methods that can quantify each peptide in the presence of the other. These are solvable problems, but they are the kind of development work that IND filings rarely describe and that clinical data cannot reveal.
The most immediate unknown is the identity of the first IND application. Ascletis disclosed two submissions but described only one. Until the company identifies the first program, outside observers cannot assess whether it is a metabolic therapy, a different indication, or a second formulation of an existing asset. This omission limits the significance of the two-IND announcement; a single disclosed program is the actual substance of the filing.
The second set of unknowns concerns the FDA review itself. Acceptance is not guaranteed, and the agency could request additional information, impose a clinical hold, or allow one application through while delaying the other. Ascletis has provided no dates for the submissions and no timeline for the FDA's review, so there is no public schedule against which to measure progress. The company has also not disclosed trial design, patient population, or endpoints for ASC36 35 FDC, which means the translational potential of the pairing cannot yet be evaluated. The key questions are straightforward. Does the fixed-dose product remain stable and bioavailable? Do the two mechanisms produce weight loss beyond either alone? And is the combination tolerated well enough that patients stay on it?
What would resolve these questions is equally clear. FDA acceptance, when it comes, will confirm only that early trials may proceed. The first meaningful scientific signal will be phase 1 data, specifically pharmacokinetic evidence that both peptides deliver predictable exposure, and tolerability data at the fixed dose ratio. Until those results appear, ASC36 35 FDC is best understood as an early regulatory bet on a scientifically reasonable hypothesis: that amylin agonism and dual incretin agonism are separate levers, and that pulling both at once may move the dial on obesity further than either can alone.
Peptides referenced: Tirzepatide, Pramlintide, Amylin, Glucagon, GLP-1.
Related reading: Bachem Holding AG Details Peptide Growth Strategy Amid Biotech Demand Rise, Bachem Holding AG Emphasizes Peptide Manufacturing and Global Pharma Demand, FDA CDER Acting Director Promotes GLP-1 Reviewer Lisa Yanoff, ADA 2026 Obesity Drug Updates: Retatrutide, CagriSema, Oral GLP-1s.